Tag Archives: Associated

Essential Reads: Modafinil and Armodafinil During Pregnancy Associated with Increased Risk of Malformations

Modafinil (brand name Provigil) and armodafinil (Nuvigil) are wake-promoting agents used to treat sleepiness due to narcolepsy, shift work sleep disorder, or obstructive sleep apnea. They are also used in other settings, often in combination with other medications, to treat ADHD symptoms, depressive symptoms, fatigue, and cognitive dysfunction.   Danish Study of 50 Modafinil-Exposed Infants In… Read More »

Treatment interruption in cure research is associated with greater risk of non-AIDS related events in the long term, Spanish study finds

A small study from an HIV hospital that has been conducting experimental treatment interruptions (ATIs) as part of research into achieving a functional cure for HIV infection has found that over a period of years, patients who had undergone ATIs had a higher risk of developing non-AIDS-related serious illnesses such as cancer, liver disease and… Read More »

Delayed HIV treatment initiation and protease inhibitors associated with erectile dysfunction in men living with HIV

Delayed HIV treatment initiation, use of protease inhibitors for more than a year, tobacco use and sleep apnoea increase the odds of erectile dysfunction among cisgender men living with HIV, according to the findings of the US Military HIV Natural History Study (NHS), published in HIV Medicine. Although HIV is associated with an increased risk… Read More »

Flu shot associated with fewer coronavirus cases, researchers suggest

Researchers at Michigan Medicine say they found an association between the flu shot and fewer, less severe coronavirus cases. The study, which reviewed medical charts for more than 27,000 patients, also found that nobody included in the data tested positive for both viruses at the same time. “It is possible that patients who receive their… Read More »

FDA Approves Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

FDA Approves Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy Print this page DUBLIN, July 22, 2020 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020 for the treatment of… Read More »